RxDoctor Payments Data

Ayaz Ahmad, MD

Internal Medicine · Saint Louis, MONPI 1629573142

Payments from drug & device makers

$1,151in general payments, 2019–2025

Across 40 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$333
  • Novo Nordisk$275
  • Lilly USA, LLC$142
  • AstraZeneca$138
  • Biohaven Pharmaceutical Holding Company Ltd.$136
  • Pfizer$63
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$1,151100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,151 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$309,196
Medicare patients
1,904
Services billed
2,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$13,033
XareltoRivaroxaban27$7,680
Humalog Kwikpen U-100Insulin Lispro41$6,539
TradjentaLinagliptin24$6,312
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$4,580
Midodrine Hcl22$1,154
Amlodipine Besylate65$857
Gabapentin44$819
Hydralazine Hcl28$699
Mirtazapine22$467
Potassium Chloride26$436
NyamycNystatin17$359
Lisinopril19$303
Levothyroxine Sodium32$284
Metformin Hcl11$182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$275$13,03313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →